Cirtec Medical Names New CEO

Cirtec Medical has appointed Shar Matin as CEO, effective Sept. 2.

“Shar is an experienced leader with a demonstrated ability to accelerate growth, strengthen customer partnerships, and drive innovation,” said Rich Relyea, Cirtec board member and 3i Private Equity partner. “On behalf of the Board, we are excited to welcome him to Cirtec and are confident he will build on the company’s strong foundation and help shape its next chapter of success.” 

Matin has more than 25 years of global leadership experience in the medical technology sector, with a proven track record of scaling businesses, driving innovation, and building strong customer partnerships. He most recently served as CEO of Cordis, where he led the successful transformation from a division of Cardinal Health to one of the world’s largest pure-play cardiovascular companies, including spearheading the acquisition of MedAlliance’s drug-eluting balloon technology.

Prior to Cordis, Matin held senior executive roles at ViewRay Technologies, Spectranetics (acquired by Royal Philips), Boston Scientific Corp., and Guidant (acquired by Boston Scientific and Abbott Laboratories). Through these roles, he consistently delivered growth through new product innovation, strategic acquisitions, and global expansion. Matin began his career as a process and manufacturing engineer.

Matin earned an MBA from Harvard Business School and a bachelor of science degree in mechanical engineering from the University of California, Berkeley. He also serves on the Board of Directors for Koru Medical Systems.

“Cirtec has tremendous momentum, and I am humbled and privileged to lead the company into its next phase of growth while building on the incredible foundation already in place,” Matin stated. “Together with our teammates and as a trusted partner to our customers, I look forward to fulfilling our mission of bringing life-changing medical technologies to market for the betterment of patient care.” 

Cirtec’s Board of Directors expressed its gratitude to Brian Highley for his leadership over the past decade. “Brian transformed Cirtec over the course of 11 years into an industry-leading CDMO with remarkable growth and expansion. His vision and commitment have been instrumental in establishing Cirtec as a trusted partner to some of the world’s most innovative medical technology companies, and we thank Brian for all his contributions to building Cirtec into the leader that it is today.” 

The Board also thanks Interim CEO Ed Philbin for his leadership over the past few months during the transition period.

Cirtec Medical designs, develops, and manufactures complex Class II and III medical devices, specializing in active implant systems, interventional devices, and precision components. Since 1987, Cirtec Medical has built in-house capabilities that enable the company to serve as a single-source partner and collaborate with customers to transform their technology into medical devices across a wide array of therapies, including cardiology, neurology, orthopedics, and other minimally invasive device applications. With 11 global facilities and a vertically integrated approach, Cirtec Medical aims to expedite time to market, reduce risk, and accelerate revenue generation for its partners.